Heim4DX • ASX
add
4DMedical Ltd
Við síðustu lokun
0,53 $
Dagbil
0,52 $ - 0,54 $
Árabil
0,41 $ - 1,10 $
Markaðsvirði
219,63 m. AUD
Meðalmagn
1,00 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
ASX
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(AUD) | jún. 2024info | Breyting á/á |
---|---|---|
Tekjur | 1,48 m. | 1.172,70% |
Rekstrarkostnaður | 12,56 m. | 11,42% |
Nettótekjur | -10,19 m. | -33,78% |
Hagnaðarhlutfall | -687,84 | 89,49% |
Hagnaður á hvern hlut | — | — |
EBITDA | -11,09 m. | -5,51% |
Virkt skatthlutfall | -0,01% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(AUD) | jún. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 30,61 m. | -56,01% |
Heildareignir | 120,02 m. | 29,16% |
Heildarskuldir | 49,09 m. | 128,71% |
Eigið fé alls | 70,93 m. | — |
Útistandandi hlutabréf | 410,53 m. | — |
Eiginfjárgengi | 3,12 | — |
Arðsemi eigna | -23,28% | — |
Ávöxtun eigin fjár | -36,73% | — |
Peningaflæði
Breyting á handbæru fé
(AUD) | jún. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | -10,19 m. | -33,78% |
Handbært fé frá rekstri | -8,06 m. | 8,54% |
Reiðufé frá fjárfestingum | -339,48 þ. | -21,29% |
Reiðufé frá fjármögnun | -233,98 þ. | -101,11% |
Breyting á handbæru fé | -8,64 m. | -172,48% |
Frjálst peningaflæði | -5,43 m. | 13,25% |
Um
4DMedical is a medical technology company, based in Australia and the United States.
4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report.
4DMedical has commercialized its XV Technology via a Software as a Service model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Wikipedia
Framkvæmdastjóri
Stofnsett
2013
Vefsvæði
Starfsfólk
145